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Background: This systematic review aimed to present and critically appraise the available information on the
efficacy of platelet rich plasma (PRP) in equine and human orthopedic therapeutics and to verify the influence of
study design and methodology on the assumption of PRP’s efficacy. We searched Medline, PubMed, Embase,
Bireme and Google Scholar without restrictions until July 2013. Randomized trials, human cohort clinical studies or
case series with a control group on the use of PRP in tendons, ligaments or articular lesions were included. Equine
clinical studies on the same topics were included independently of their design. Experimental studies relevant to
the clarification of PRP’s effects and mechanisms of action in tissues of interest, conducted in any animal species,
were selected.
Results: This review included 123 studies. PRP’s beneficial effects were observed in 46.7% of the clinical studies,
while the absence of positive effects was observed in 43.3%. Among experimental studies, 73% yielded positive
results, and 7.9% yielded negative results. The most frequent flaws in the clinical trials’ designs were the lack of a
true placebo group, poor product characterization, insufficient blinding, small sampling, short follow-up periods,
and adoption of poor outcome measures. The methods employed for PRP preparation and administration and the
selected outcome measures varied greatly. Poor study design was a common feature of equine clinical trials. From
studies in which PRP had beneficial effects, 67.8% had an overall high risk of bias. From the studies in which PRP
failed to exhibit beneficial effects, 67.8% had an overall low risk of bias.
Conclusions: Most experimental studies revealed positive effects of PRP. Although the majority of equine clinical
studies yielded positive results, the human clinical trials’ results failed to corroborate these findings. In both species,
beneficial results were more frequently observed in studies with a high risk of bias. The use of PRP in
musculoskeletal lesions, although safe and promising, has still not shown strong evidence in clinical scenarios.
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Musculoskeletal lesions are a common consequence of
physical overstrain, which negatively impacts quality of
life and athletic performance. Specifically among both,
equine and human athletes, treating persistent or slow
healing injuries poses a challenge for clinicians. These
lesions, which frequently result in inadequate tissue
reorganization and thus in a high re-injury rate, are
often related to a long period of incapacity or to an
unsatisfactory return to performance [1].
Hemoderivatives have been reported to be beneficial
in scenarios in which efficient, cost-effective and safe
forms of orthopedic interventions are necessary to
restore the normal function and structure of musculo-
skeletal components and in which health care profes-
sionals are tempted to explore promising forms of
therapy. The use of patients’ own biological materials for
tissue healing and therapeutic purposes offers a safe and
interesting alternative to conventional treatments, and
such materials often lack side effects. Presently, several
blood-derived products are available for intra-lesional in-
jection, such as platelet-rich plasma (PRP) or plasma
rich in growth factors, autologous conditioned serum,
autologous blood preparations and autologous protein
concentrate [1-6].
The rationale behind the injection of autologous blood
preparations lies in the exploitation of advantageous
mechanisms of the body’s natural response to injury,
whether the platelets’ ability to induce hemostasis and to
release growth factors [7,8] or the production of anti-
inflammatory cytokines by blood components [5,9].
Blood is an important and unique source of cellular and
protein products that has been explored more inten-
sively over the last three decades for the production of
biomaterials for clinical use [4]. A considerable number
of data have suggested beneficial effects associated with
their use, but these findings have not been unanimous
when experimental and clinical trial’ results have been
compared.
Platelet-rich products, in particular, have gained popu-
larity for their increased concentrations of growth fac-
tors, but their compositions encompass much more than
these factors. A myriad of other blood-derived sub-
stances such as fibrin and leukocytes are contained
within these products, characterizing PRP as a complex
and unique mixture, with donor-related properties and a
yet unrevealed spectrum of active blood components
[10]. Platelet concentrates with distinct compositions,
and therefore distinct applications, are referred to as PRP.
Some authors have proposed a more accurate termin-
ology, along with a thorough description of the platelet
concentrate. Using this terminology four different prod-
ucts can be recognized according to their fibrin architec-
ture and leukocyte content: pure platelet-rich plasma,leukocyte and platelet-rich plasma, pure platelet-rich
fibrin and leukocyte- and platelet-rich fibrin [11].
The cellular and molecular content of platelet concen-
trates also depend on the method or kit used for their
preparation. Until now, there has been no consensus on
which processing method yields the best platelet- related
product for a particular purpose, and patented and non-
patented technologies and procedures have been used in
clinical and experimental scenarios [12].
During athletics, both horses and humans are subjected
to escalating stresses to their appendicular systems, to
compete successfully. These increasing demands are ac-
companied by a multitude of orthopedic lesions, for which
conventional therapies have proven partially helpful.
The objectives of this systematic review were to assess
the effectiveness of PRP in the healing of tendon, ligament
and articular lesions in equine and human patients, to
compare the results from clinical and experimental studies
in both species, and to verify the existence of a relation-
ship between the study designs and results of clinical tri-
als. This review also aimed to evaluate critically the
existing evidence to provide clinicians with high-quality
information and a more thorough appreciation of the
effects of the diversity of PRP’ processing techniques.Methods
This systematic review was performed in accordance with
the PRISMA (Preferred Reporting Items for Systematic
Reviews and Meta-Analyses) statement, an evidence-
based, established guideline for systematic reviews pub-
lished by the CONSORT group [13,14].
A comprehensive literature search addressing the use
of hemoderivatives in orthopedic lesions was conducted
in July 2013 for all relevant articles in English, French,
German, Spanish and Portuguese without publication or
date restrictions, and all of the authors (PMB, JJM,
TSLM, RYAB) were involved. The Embase, Bireme,
Medline, PubMed and Google Scholar databases were
used, with the search terms “platelet rich plasma”,
“PRP”, “tendon”, “joint”, “articular”, “ligament”, “muscu-
loskeletal injuries”, “human” and “equine”. Additional
studies were identified by searching the reference lists of
eligible articles. Studies that used PRP in conjunction
with stem cells or other biomaterials, as regenerative/
anti-inflammatory therapies for other target tissues (e.g.,
bone) or in other medical fields (such as ophthalmology,
craniomaxillofacial or plastic surgery) were excluded.
Equine clinical studies, because of their scarcity, were
included independently of their design or level of evi-
dence if they described the effects of PRP on tendon,
ligament or articular injuries. Human clinical studies
were included if they reported the use of PRP in tendon,
ligament or articular lesions and were either double-
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or if they were case series with a control group.
Experimental studies with PRP conducted in several
species, both in vivo and in vitro, were selected if they
were controlled and relevant to the clarification of the
effects and mechanisms of action of PRP in tissues of
interest. Studies that used products not derived from
blood processing, despite an analogous function or a
similar composition to PRP, were not included [15-17].
Preliminarily, the abstracts and titles were reviewed to
select manuscripts for full-text review. Relevant data
were then extracted from the selected articles based on
predefined data fields and were sorted in tables corre-
sponding to clinical and experimental studies, independ-
ently, by all of the authors. The tables were intended to (1)
facilitate the identification of the lesion/tissue/population
studied; (2) characterize the control and intervention
groups; (3) state the outcome measures and methods
employed for the evaluation of effects; (4) describe in
detail the method of preparation, composition and proto-
col of administration of PRP; and (5) present the results
and rate them as positive or beneficial (+), partially posi-
tive (±) or negative (impartial) (−). This assessment was
not made by the review’s authors and is in accordance to
the results presented, when confronted with the selected
outcome measures. This overall view of the studies’ design
and contents was followed by annotation of weak points
that could have negatively affected the generation of qual-
ity evidence or that could have biased the studies’ results.
Experimental studies with in vivo and in vitro ramifica-
tions had their results presented on separate lines to allow
for a thorough analysis.
The risk of bias of the selected clinical trials was pre-
sented in tables according to PRISMA guidelines, and
the studies were assigned as having a high or a low risk
of bias if they exhibited, respectively, more or fewer bias
criteria. This information, together with the analysis of
the clinical trials’ results, was used to verify a possible
association between these two variables and was also
presented in tables.Results
Our search parameters yielded 7415 results: 3563 from
Embase, 2817 from Bireme, 101 from Medline, 122 from
PubMed and 812 from Google Scholar. Fifteen studies
were identified in reference lists from the selected arti-
cles. The titles and abstracts of the retrieved records
were screened for eligibility, and 5926 studies were thus
excluded. One thousand five hundred four articles were
fully assessed. One hundred twenty-three (123) articles
were selected after the exclusion criteria (i.e., the exclu-
sion of duplicates, review articles, non-controlled human
trials, studies in which other tissues were examined andexperimental studies investigating PRP preparation
particularities) were applied (Figure 1).
Among these 123 studies, a relatively homogeneous
distribution between clinical trials (60 studies or 48.8%)
and experimental studies (63 studies or 51.2%) was
observed. These 123 articles yielded 126 results because
two experimental studies comprised both in vivo and in
vitro experiments, which were considered separately.
Clinical trials with PRP
From the 60 clinical studies included in this review, 11
(18.3%) [18-28] were conducted in horses, and 49
(81.7%) [29-77] were conducted in humans. Considering
both species together, the results of the clinical trials
were evenly distributed, that is, beneficial effects were
observed in 28 studies (46.7%) [19,21-23,25,26,28,29,32,
34-36,38,39,41,49,55,57,58,62,64,69,70,72-76], and nega-
tive effects were observed in 26 studies (43.3%) [18,30,
31,33,37,42-45,47,48,50-54,56,59,60,63,65-68,71,77] after
PRP application (Additional file 1: Table S1).
Analyzing the species separately, we observed that the
distribution of results was not homogeneous and that
positive results were more frequent than negative results
in the equine species. Seven [19,21-23,25,26,28] of 11
equine clinical trials yielded positive results (63.6%),
three [20,24,27] resulted in partially positive results
(27.3%), and one (9.1%) [18] yielded a negative result. In
contrast, of the 49 human clinical studies, 21 yielded
positive results (42.8%) [29,32,34-36,38,39,41,49,55,57,58,
62,64,69,70,72-76], while 25 studies (51%) [30,31,33,37,
42-45,47,48,50-54,56,59,60,63,65-68,71,77] yielded nega-
tive results, and 3 (6.1%) [40,46,61] resulted in partially
positive results.
Although the percentages of negative and positive re-
sults in the human clinical trials were fairly even, the
study design distribution among the positively and nega-
tively evaluated studies was not homogeneous. This dis-
tribution revealed a negative correlation between a
rigorous study design and the finding of beneficial re-
sults associated with the clinical use of PRP. Thirty-five
studies were classified as RCTs: 34 [29,30,32-40,43,44,46,
47,49-54,56,57,59,61-63,66-68,70,71,75,77] from the hu-
man medical literature and one [18] from the equine
medicine literature. Among them, 12 trials (34.3%)
[29,32,34-36,38,39,49,57,62,70,75] yielded positive re-
sults, while 20 RCTs (57.1%) [18,30,33,37,43,44,47,
50-54,56,59,63,66-68,71,77] yielded negative results, and
3 RCTs (8.6%) had [40,46,61] mixed results.
Among the remaining 10 equine clinical trials that
were not RCTs, seven studies [19,21-23,25,26,28] that
yielded positive results were uncontrolled trials. Overall,
2 studies (18.2%) [18,24] had control groups, and eight
[19,21-23,25-28] uncontrolled case series accounted for
72.7% of the equine studies. The remaining 15 human
Figure 1 Flow diagram for identification of published studies. PRISMA 2009.
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were not RCTs were controlled retrospective or pro-
spective cohorts, comparative studies, case control series
and observational controlled studies.
Additionally, while 76.9% (20/26) of the studies
[18,30,33,37,43,44,47,50-54,56,59,63,66-68,71,77] with
negative results were classified as RCTs, 42.8% (12/28)
of the studies [29,32,34-36,38,39,49,57,62,70,75] with
positive results were RCTs.
Regarding study design, the lack of a true placebo con-
trol group was the most frequently assigned flaw. Forty-
three studies (71.7%) [24,29-32,35,38-44,46-55,57-76]
had control groups that differed from placebo, such as
hyaluronic acid and corticosteroids, and/or that included
physiotherapy, excentric exercises, peppering techniques,
dry needling (or combinations of these techniques) or
merely lack of PRP application. Nine studies (15%)[19-23,25-28] lacked a control group, and all of these
studies were conducted in horses.
Poor PRP characterization was a feature of 35 clinical
studies (58.3%) [20,24,29-33,35-38,42-47,49,50,53,55-60,
62-64,67,68,71,73,76,77] and was the second most fre-
quent flaw. Information regarding PRP preparation, acti-
vation and composition was not always provided in a
complete manner, and in one clinical trial [60], this in-
formation was not provided at all. The product name, a
description of the processing method in detail and a de-
scription of PRP activation when used (or stated other-
wise) defined adequate hemoderivative characterization.
Platelet and leukocyte concentrations, together with
their concentration factors from baseline levels and an
analysis of growth factor contents, should ideally have
been stated. Of 60 clinical trials, eight (13.3%)
[21,22,25,27,28,51,69,72] provided this standard of
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39-41,48,52,54,61,65,66,70,74,75] provided only average-
quality information on the employed hemoderivative; no
data on growth factor content were provided.
The methods employed for PRP preparation have
been the object of controversy [1,7]. Of the 60 clinical
studies, 30 (50%) [18,19,23,29,31-36,38,39,46,51,53,54,
56,57,62-64,67-70,72,73,75-77] employed only one cen-
trifugation, 19 (31.7%) [21,24,25,27,28,42-45,47,49,50,
52,55,58,59,65,66,71] employed two centrifugations, and
one [41] employed three centrifugations. Filtration was the
method of choice for obtaining PRP in one study [22], and
nine studies [20,26,30,37,40,48,60,61,74] did not state how
many centrifugations were employed for PRP preparation.
Of the 30 studies that employed one centrifugation, 18
yielded positive results (60%) [19,23,29,32,34-36,38,39,57,
62,64,69,70,72,73,75,76]. Of the 19 studies that employed 2
centrifugations, 6 yielded positive results (31.6%) [21,25,
28,49,55,58].
Regarding PRP activation, 23 studies [18,23,24,29-33,
35,37,38,41,47,51,53,54,56,57,60,62,63,76,77] did not stipu-
late whether their product was activated or not. Overall,
35 studies (58.3%) [19-21,25-28,33,36,39,40,42-46,48-50,
52,55,58,59,61,65-75] used activators together with PRP.
Calcium was used in 23 studies [19,21,25,27,28,33,36,39,
42-45,48-50,52,55,58,59,65,66,69,72] thrombin in five
[20,61,67,73,74], and calcium and thrombin in combin-
ation in six [40,46,68,71,73,74]. In two studies [22,64], the
PRP was not activated.
Insufficient blinding was the third most common flaw
in design and was found in 33 studies (55%) [18-31,35,
37-41,45,48,55,58,60,65,67,69,72-76]. Adequate blinding
was defined as the outcome assessors, patients and treat-
ing physicians being blinded to the treatment or inter-
vention that was applied. Among the 33 non-blinded
studies encountered in this review, 19 (57.6%) [19,21-23,
25,26,28,29,35,38,39,41,55,58,69,72-74,76] had favorable
results associated with PRP intervention, and ten (30.3%)
[18,30,31,37,45,48,60,65,67,77] yielded negative results.
The fourth most frequent flaw, occurring in 32 studies
[18-28,30,35,37,40,43,45,46,51,52,56,58,59,61,64,65,67,70,
72,75-77] (53.3%), was the enrollment of a smaller-than-
desired number of subjects. A study was considered to
have a small sample when this information was
provided by the respective authors, based on power
calculations of the selected population. Among the 28
studies in which PRP had positive effects, 14 (50%)
[19,21-23,25,26,28,35,58,64,70,72,75,76] had a small
sample, and among the 26 studies in which PRP inter-
vention resulted in negative outcomes, 12 (46.1%)
[18,30,37,43,45,51,52,56,59,65,67,77] enrolled a smaller-
than-desired sample.
The adoption of a short follow-up period, that is, an
observation period of less than 12 months, also occurredin 32 studies (53.3%) [20,23,29,32-42,51,53-55,59-61,63,
65,67-71,73-75,77]. Among the 26 clinical trials with
negative results, 12 (46.1%) [18,30,31,43-45,47,48,50,52,
56,66] were considered to have sufficient duration.
Among the 28 studies with positive results, 13 (46.4%)
[19,21,22,25,26,28,49,57,58,62,64,72,76] were considered
to have an appropriate follow-up period.
Inadequacy of the parameters for outcome evaluation
was a feature of 29 studies (48.3%) [18,24-26,28,29,31,32,
34,36-39,41,42,51,54,55,57,61-64,67,69,70,74-76]. Among
the 26 studies with negative results, 8 [18,31,37,42,51,
54,63,67] adopted inadequate outcome measures (30.8%).
Among the 28 studies with favorable results, 19 [25,26,
28,29,32,34,36,38,39,41,55,57,62,64,69,70,74-76] had inad-
equate outcome measures (67.8%), and nine studies
[19,21-23,35,49,58,72,73] were classified as having ad-
equate outcome measures.
Not only study design but also the evaluation of the
risk of bias of individual studies showed relationships
between studies with a higher risk of bias and positive
(beneficial) results observed after PRP interventions,
with 67.8% (19/28) [19,21-23,25,26,28,29,34,38,39,41,55,
58,69,72-74,76] of high-risk studies having positive
outcomes. Of the studies rated a low risk, 28.6% had
favorable outcomes. Among all of the studies in which
PRP did not positively affect the selected outcomes,
73.1% (19/26) [18,30,33,37,43,44,47,50-54,56,59,63,66,
68,71,77] were attributed a low risk of bias (Table 1
and Figure 2).
Side effects associated with PRP use in the clinical set-
ting were observed in two studies (3.3%); in one study
[18] they referred to swelling at the injection site and in
another [45] they related to infection after platelet-rich
fibrin matrix application.
The majority of in vivo trials were devoted to observ-
ing the effects of PRP on tendinopathies (29 studies or
46%) [19-21,24,27,30,32,33,35,40,43-45,48-54,56-58,60,
62,-63,65,72,76], followed by articular disorders (18
studies or 28.6%) [24,25,28,34,36-39,41,47,55,59,68-70,
73-75] and ligament disorders (16 studies or 25.4%)
[18,21-23,26,27,29,31,42,46,61,64,66,67,71,77]. The sum
of recorded lesion locations (63 injury sites) exceeded
the total number of clinical articles selected because a
few studies observed the effects of PRP on both
tendons and ligaments [21,23,27]. Considering 63
observation points, the injured tissues that were more
positively affected by PRP treatment in in vivo trials
were cartilage (20.6%) [25,28,34,36,38,39,41,55,69,70,
73-75] and tendons (17.5%) [19,21,23,32,35,49,57,58,
62,72,76] followed by ligaments (9.5%) [21-23,26,29,64].
Among the studies of arthropathies, 72.2% yielded
positive results. In addition, 37.9% of the studies of
tendinopathies yielded positive results, and 37.5% of
the studies of desmopathies yielded positive results.



















































Garret 2013 + + - + - + + - ↓
Zuffova
2013
- - - - - + + + ↑
Edinger
2012
- - - - - - - - ↑
Torricelli
2011
- - - - - + + + ↑
Castelijns
2011
- - - - - + + + ↑
Georg 2010 - - - - - + ? - ↑
Abelanet
2009
- - - - - + + - ↑
Carmona
2009
- - - - - + + + ↑
Waselau
2008
- - - - - + + + ↑
Arguelles
2008
- - - - - + + + ↑
Carmona
2007
- - - - - + + + ↑
Tiwari 2013 ? - - - ? + + - ↑
Antuna
2013
+ + - + + + + + ↓
Magnussen
2013
- - - - - + + + ↑
Mishra 2014 + + - + + + + + ↓
Krogh 2013 + + - + + + + + ↓
Patel 2013 + ? ? ? ? + + - ↑
Wasterlain
2012
+ + - + + + + + ↓
Jain 2012 + + + + + + + + ↓
Mardones
2012
+ + + + + + + + ↓
Cerza 2012 - - - - - + + + ↑
Mei-Dan
2012
+ - - - + + + + ↑
Almeida
2012
+ - - - + + + + ↓
Spaková
2012
- - - - - + + + ↑
Aksahin
2012
- - - + - + + + ?
Rodeo 2012 + + + + + + + + ↓
Weber 2012 + - + + + + + + ↓
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Table 1 Risk of bias of selected clinical studies (Continued)
Bergeson
2012
- - - - + + + + ?
Cervelin
2012
+ + ? - + + + - ↓
Filardo
2012
+ + + + + + - + ↓
Jo 2011 - - - - - + + + ↑
Randelli
2011
+ + + + + + + + ↓
Castricini
2011
+ + + + + + + + ↓
Thanasas
2011
+ + - + + + + + ↓
Schepul
2011
+ + + + + + + + ↓
De Vos
2011
+ + + + + + + + ↓
Creaney
2011
+ + + + + + + + ↓
Kon 2011 - - - - - + + + ↑
Jonge 2011 + + + + + + - + ↓
Gosens
2011
? ? + + + + + + ↓
Barber 2011 - - - - - + + + ↑
Horstman
2011
+ + + + + + + + ↓
Buford
2011
- - - - - + + + ↑
Vogrin 2010 + + + + + + + + ↓
Peerboms
2010
+ + + + + + + + ↓
De Vos
2010
+ + + + + + + + ↓
Radice 2010 - - - - + + + + ?
Filardo
2010
- - - - - + + - ↑
Nin 2009 + + + + + + + + ↓
Silva 2009 - - - - - + + + ↑
Peerboms
2009
? + + + + + - + ↓
Sanchez
2008
- - - - - - ? + ↑
Everts 2008 + + + + + + + + ↓
Orrego
2008
+ + - + + + + + ↓
Sanchez
2007
- - - - - + + + ↑
Everts 2007 - - - - - + + + ↑
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Gardner
2007
- - - - - + + + ↑
Zavadil
2007
+ + + + + + + + ↓
Mishra 2006 - - - - - + - + ↑
Ventura
2005
+ + - - - + + + ↓
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In total, 63 experimental studies were included in this
review: 13 (20.6%) [78-90] were conducted in horses, 16
(25.4%) [91-106] were conducted in humans and 34
(54%) [107-140] were conducted in other species.
Overall, their results contrasted with those of the clinical
trials. Regarding outcomes, the homogeneity of the distri-
bution between beneficial and negative results observed in
the clinical trials was not mirrored in the experimental sce-
nario. Among the 63 experimental studies, 46 (73%)
[81-86,88,90-95,97-103,105-110,112,115,118-122,124-129,
131,134-137,139,140] yielded positive results, 12 (19%)
[78,79,87,89,96,104,111,113,116,123,130,133] yielded mixed
results, and five (7.9%) [80,114,117,132,138] yielded nega-
tive results. Among the five experimental studies with nega-
tive results, all of them were conducted in vivo; four of
them included mechanical evaluations among their out-
come measures [80,117,132,138]. Two studies [114,132] ex-
hibited side effects associated with PRP administration, and
one study [114] failed to show improvements during the
histological evaluation of experimentally induced tendon le-
sions treated with PRP.Figure 2 Association between risk of bias and clinical studies’ results.From the 63 experimental studies, 35 (55.5%)
[79,80,82-85,90,107,109-114,116-121,123-128,130-133,1-
35-139] originated from in vivo experiments, 23 (36,5%)
[81,86-89,91-103,105,108,115,133,139] originated from
in vitro work, and five (7.9%) [78,96,104,106,122] origi-
nated from both in vivo and in vitro experiments
(Additional file 2: Table S2). Considering separately the
results of the five experiments conducted both in vivo
and in vitro there are 67 experimental results. From the
41 in vivo trials, 27 (65.8%) [82-85,90,96,106,107,109,
110,112,118-122,124-130,134,136,137,139] yielded posi-
tive results, while 23 of the 26 (88.5%) [81,86,88,
91-103,105,106,108,115,122,134,140] in vitro experi-
ments had positive results.
Considering only equine and human studies, there
were 23 (79.3%) [81-86,88,90-103,105,106] positive re-
sults, 5 (17.2%) [78,79,87,89,104] mixed results and one
(3.4%) [80] negative result.
Among the 12 experiments with partially positive re-
sults, nine (75%) [78,79,96,111,113,116,123,130,133] were
conducted in vivo. Different reasons for adverse outcomes
were observed. In one experiment [78], the PRP
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factor content. In two experiments [78,79], side effects re-
lated to PRP administration were observed. In another
two experiments [111,130], PRP treatment did not re-
sult in hyaline cartilage formation. In four studies
[113,116,123,133], the treated tissues did not satisfac-
torily withstood mechanical challenges and in one trial
[96], gene expression was not affected by PRP. In two
in vitro trials with partially positive results [87,89],
equine suspensory ligament explants cultured with PRP
had increased gene expression, but this rate was greater
when acellular bone marrow was added to the cultures,
and in one [78] PRP preparation resulted in an insuffi-
cient increase in growth factor content.
In total, side effects were observed in five experiments
[78,79,114,117,132]. One study [114] observed local re-
actions at different injection sites and concluded that
PRP was capable of initiating an inflammatory response
in the absence of an injury. In a second trial [117], a cel-
lular response around grafts for anterior cruciate liga-
ment (ACL) reconstruction was noted. In two studies
[78,79], thrombin-activated PRP elicited both a local and
a systemic inflammatory response after intra-articular
injections in horses. Others (132) noticed cellular infil-
tration and fibroid necrosis 7 days after PRP application
in a rotator cuff repair model.
Regarding PRP characterization, 16/63 (25.4%) experi-
ments [78,79,81,87,88,90,98,100-103,105,113,125,135,140]
exhibited good product characterization; in 26 studies
(41.3%) [82,85,86,92-94,96,97,99,104,106-108,111,112,114,
116,117,122,126,128-130,134,136,137] the hemoderivative
was satisfactorily described, and in 21 (33.3%) [80,83,
84,89,91,95,109,110,115,118-121,123,124,127,131-133,138,
139] experiments, the characterization was considered
unsatisfactory.
Activation was employed in 39 experiments (61.9%)
[78,79,82,85,92,94,96-108,110,112-114,116,117,119-122,
125-127,129,130,132,134,136,137,140], and PRP activa-
tion was not mentioned in 23 experiments (36.5%)
[80,81,83,84,86-91,93,95,109,111,115,118,123,124,130,
133,135,138,139]. One study [128] stated that the
hemoderivative was not activated.
For the preparation of PRP in experimental studies a
single centrifugation was the method chosen for PRP
preparation in 29 experiments (46%) [81,83,84,86-91,94,
97,98,100,103-105,109-111,113,118-121,124,125,128,133,
139]. Two centrifugations were used in 29 (46%)
[80,82 ,92,95,96,99,101,106-108,112,114-117,122,123,126,
127,129-132,134-138,140] experiments, one and two
centrifugations were used in one experiment [93] and 3
centrifugations were employed in two experiments
[85,102]. Filtration was used to obtain PRP in two trials
[78,79]. Among the 29 experiments that employed one
centrifugation, 25 yielded positive results (86.2%)[81,83,84,86,88,90,91,94,97,98,100,102,103,105,109,110,1-
18-121,124,125,127,139,140]. Of the 29 experiments
that employed two centrifugations, 20 yielded positive
results (75%) [82,92,94-96,99,101,106-108,112,115,122,
127,131,134-137,140].
Among the 67 experimental results, 17 were con-
ducted in humans [91-106], 15 in rabbits [113-127], 13
in horses [78-90], ten in rats [128-137], five in sheep
[96,104,110-112], three in pigs [138-140], three in dogs
[107-109] and one in mice [96]. The number of species
exceeds the number of experiments because, in a few
cases, in vivo and in vitro trials of a same experiment
yield two results in the species count down.
Thirty-five experiments (55.5%) [80,81,83-85,88,90-97,
102,104-106, 108,110,116,119-121,124,125,128,129,131-
137] were related to tendon disorders, 16 (25.4%)
[78,79,82,98-101,103,111,112,115,123,126,127,130,140]
to cartilage, ten (15.9%) [87,89,107,109,113,117,118,122,
138,139] to ligament lesions, one (1.6%) [86] to both
ligament and tendon disorders, and one (1.6%) [114] to
several potential injury tissues. PRP yielded positive
results in 85.7% of the experiments with tendons (30 tri-
als) [81,83-85,88,90-95,97,102,104-106,108,110,119-121,
123,124,128,129,131,134-137], 68.7% (11 trials) of those
with cartilage [82,98-101,103,112,115,126,127,140], and
50% of those with ligaments (five trials) [107,109,
118,122,139].
Discussion
The use of hemoderivatives for tissue healing has gained
increasing popularity for the treatment of musculoske-
letal lesions. Among these derivatives, PRP has already
been established as a part of the repertoire of possibil-
ities for the treatment of orthopedic conditions
[4,6,10,141-147].
Despite widespread acceptance of its ambulatory use, re-
search continues for the purpose of providing convincing
evidence of clinical benefits associated with this hemoderi-
vative’s administration. Uncontrolled or biased reports of
PRP’s efficacy have been excessive and have not strength-
ened the existing evidence, suggesting (but not definitively
demonstrating) the beneficial effects of PRP.
The overall quality of the study design was less than
ideal in the majority of the selected studies and the qual-
ity was inversely correlated with the performance of PRP
in clinical trials. Rigorous study design and a low risk of
bias were associated with negative outcomes in PRP clin-
ical trials. Because a high-quality study design was a
much more common feature of human studies and a
rare feature of equine studies, it was not surprising to
find more negatively affected outcomes in human clin-
ical trials and positive outcomes in equine clinical trials.
Other authors have emphasized the importance of well-
designed clinical studies for the evaluation of PRP’s
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about their scarcity [141,146,148-156], but the present
review presented a quantitative link between study
design and outcome.
Accordingly, 76.9% of the studies with negative results
were classified as RCTs, while RCTs comprised only
42.8% of the studies with positive results. While the in-
clusion of studies with different designs can be a subject
to debate if, in one hand, the inclusion of RCTs, cohorts
and controlled case series caused heterogeneity of our
study sample, on the other, the diversity and the large
number of studies included allowed for comparisons and
for the establishment of a quantitative relationship be-
tween study design and outcome after PRP intervention.
This relationship was more consistent in the human
clinical trials, given the scarcity of RCTs and controlled
studies in the equine species. As expected, the majority
of less than ideally- designed equine studies yielded posi-
tive results, and the only negative result among equine
clinical trials originated from the only equine RCT. The
same was true for including data of clinical and experi-
mental studies, but, again, the comparison between re-
sults of PRP´s efficacy with these different
methodologies revealed important results.
Another purpose of the current review was to analyze
and summarize the most common flaws in study design
and to evaluate their implications in the results of PRP
interventions. The most striking feature contributing to
the debatable quality of the clinical trials included in this
review was the lack of a true placebo control group. This
observation referred mainly to the human clinical trials
because the majority of the equine clinical trials lacked a
control group, thereby preventing comparison.
Because several of the selected studies adopted sub-
jective outcome measures and lacked a true placebo
control group, their results could have been impacted.
However, a gold standard treatment, if one exists, can be
assigned to the control group for comparison with a
new proposed treatment. Then, researchers would be
comparing two active treatment groups, without a pla-
cebo group [157]. This comparison was frequently ob-
served in this review, and PRP’s effectiveness was often
compared with that of hyaluronic acid, corticosteroids,
autologous blood injections, no treatment, dry needling,
physiotherapy or combinations of these therapies. Never-
theless, treatment controls, such as sham acupuncture
and intra-articular hyaluronic acid, have a greater effect
size than the average placebo effect [158]. Although con-
trol groups were often assigned to some sort of treatment
in the selected articles, we could not identify relationships
between positive or negative results and the lack of a true
placebo group. In addition, as other authors [159] have
mentioned, the use of PRP combined with other biological
therapies could pose a challenge to the evaluation of PRP’sindividual effects and confound interpretation of the
results. Therefore, studies that chose to do so were not in-
cluded in this review.
Poor hemoderivative characterization was the second
most common flaw contributing to the assignment of
study design as not ideal. Inconsistencies associated with
PRP preparation and administration have contributed to
the lack of strength and to the disparities of the generated
evidence regarding PRP’s efficacy, in both clinical and ex-
perimental studies [160]. The most important conse-
quence of the confounding diversity of the methods
employed for PRP processing was the difference in result-
ing final products, which precluded a comparison of the
treatment’s results [143,149,156]. Similar to any autolo-
gous blood-derived product, PRP has unique, non-
reproducible and donor-related features that can
jeopardize a comparison of the results [161,162]. There-
fore, the hemoderivate composition should be verified and
clearly presented [81,163] to minimize these effects.
This review confirmed the existing diversity of prep-
aration methods, commercial or laboratorial, for
obtaining PRP, as already indicated by other researchers
[12,81,149,156,164-166]. These methods might include
single, double or triple centrifugations, filtration and
plateletpheresis, with and without the aid of activating
agents. Most of the selected clinical studies employed
one centrifugation step, and more positive results were
observed with this method. Previous studies have dem-
onstrated that a double centrifugation method resulted
in higher platelet concentrations [167,168], but caused
more alterations in platelet morphology and was more
sensitive to small errors during preparation [168,169]
compared with the single centrifugation method. This
trend toward more positive outcomes with PRP pre-
pared with one centrifugation step must be confirmed
with further research. Overall, PRP characterization
was more adequate in the experimental studies than in
the clinical trials.
Another controversial topic in PRP preparation has been
the need for activation – or the lack of it [163,170-172]. Until
a consensus is reached, comparing activated to non-activated
products is inevitable. Most of the clinical and experimental
studies activated PRP before injection, and clinically more
positive outcomes were observed without PRP activation.
The percentages of clinical and experimental studies that
employed activation were similar. Experimentally, there was
no relationship between the use of activation before PRP ad-
ministration and favorable or unfavorable outcomes.
The administration protocols also varied greatly among
the studies - clinical and experimental - regarding injec-
tion or application techniques, volume of hemoderivative
employed and timing and frequency of administration.
Again, all of these variables limited our ability to compare
the results from different articles [148,166].
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feature of the studies designs. Blinding limits bias in out-
come evaluation, and whenever feasible, outcome asses-
sors should not be aware of the treatment allocations of
the patients in a clinical study [173]. Blinding of out-
come assessors is one of the safeguards to assure the in-
ternal validity of a trial, and there has been strong
evidence that their unblinding exaggerated treatment
effects. Particularly when scoring subjective outcomes,
for instance pain scores, biased findings can result from
inadequate blinding [157,174]. Blinding becomes less
important in reducing observer bias, as the outcome
measure becomes less subjective [157]. In addition to
the blinding of outcome assessors, trial participants and
investigators should be unaware of an assigned interven-
tion for similar reasons.
The adoption of a short follow-up period and the enroll-
ment of a small sample were the fourth most commonly
encountered weaknesses in study design, particularly in
horses. Inadequate duration of follow-up or treatment
compromises the external validity of an RCT. Clinicians
treating patients with a variety of conditions have called
attention to the contrast between the beneficial effects of
treatments in short-term RCTs and the less encouraging
experiences with long-term treatment in clinical practice
[175]. Long-term follow-up evaluations should be a prior-
ity [81]. In this review, the classification of short study
duration was evenly distributed between studies with posi-
tive and negative results and did not particularly affect
outcomes, although a few clinical trials showed the short-
term efficacy of PRP in improving knee function and qual-
ity of life [55,176].
The detrimental effects of enrolling a small sample on
the power of a study have been well documented. When
a sample is too small, a study is particularly susceptible
to a type II errors; that is, the study could be insuffi-
ciently powerful to detect real differences between
observed groups. Calculations of explicit sample size or
power to anticipate this error have rarely been
performed before the start of a research study [177].
However, in the selected articles, smaller samples were
not particularly associated with positive or negative out-
comes. Nevertheless, we encourage authors to enroll
sufficient numbers of subjects in their studies to assure
adequate power and significance to their findings.
The adoption of inadequate outcome measures was
the fifth most frequently encountered weakness in study
construction in this review. As already mentioned sub-
jective outcomes present great opportunities for bias
[174] and frequently were the only type of employed
outcome measure in the selected studies.
In orthopedic research, health status can be assessed by
a number of methods, which are classified either as
objective (e.g., radiological changes, range of motion) or assubjective (those relying on responses obtained directly
from patients about their perceptions of health and
illness) and as either generic or disease-specific [174].
Most authors have accepted that a combination of object-
ive and subjective measures is desirable for conducting a
complete assessment. Often, a single given parameter
employed for outcome evaluation suits certain circum-
stances but not others, and there has rarely been a single
most appropriate rating system or outcome measure
[173,178,179]. Employing different outcome measures
allows for the capture of diverse aspects of overall func-
tion, and lack of agreement between patient-reported and
objective measures reflects this diversity, rather than indi-
cating a weakness in one method or the other [180].
In this review, 48.3% of the selected studies only evalu-
ated PRP treatment’s efficacy with a few questionnaire-
reported or subjective measures, as opposed to the ideal
multifaceted evaluation; therefore, they were classified as
having poor outcome measures. It is important to
choose the most adequate measures for a particular task,
condition and setting; otherwise, the results of clinical
research can be misleading. In particular, the inclusion
of mechanical tests resulted in more outcomes that were
negative in the experimental studies. This association
might help to explain why the consistently positive
responses induced by PRP in vitro, particularly in cell
cultures, were not correlated with similar improvements
in outcomes in vivo. Another aspect that added confu-
sion to the comparison of results of PRP treatments
among the studies was the variety of lesions treated.
PRP’s performance was compared in acute and chronic;
experimentally induced and naturally occurring; tendon,
ligament and articular disorders without due distinction
for the particular tissues’ characteristics. Biomechanical
particularities, such as those of the flexor and extensor
tendons; lesion localization, such as insertional versus
body tears in ligaments; and staging of lesions, such as
advanced osteoarthritis versus mild cartilage injuries,
were not considered when evaluating PRP’s treatment ef-
ficacy [166,177].
The localization of lesions in the clinical trials was
associated with both positive and negative outcomes.
PRP intervention yielded more positive results in tendi-
nopathies than in arthropathies and desmopathies in
humans. In a large survey of PRP’s effects in the equine
species in which 191 subjects were treated for desmopa-
thies, tendinopathies and arthropathies, good results
after intralesional injection were obtained, but in tendi-
nopathies results were more impressive [181]. The
reasons for these findings are unknown, and given the
heterogeneity of tissues and stage of diseases, these
results should be interpreted with care. Other re-
searchers failed to provide definite recommendations for
PRP intervention on a tissue-related basis [164]. Clinical
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distinct phases of lesion progression, different species
and particularly-affected structures do affect perform-
ance of a treatment modality and must be considered.
This review demonstrated that scientific evidence of
the beneficial effects of PRP in clinical settings remains
lacking. While the vast majority of experimental in vitro
studies yielded positive results, the same promising out-
comes were not verified in the clinical trials after interven-
tion with PRP, particularly in humans. Corroborating
these observations, we found that all of the negative
results from experimental works came from in vivo stud-
ies. Other authors have made similar remarks when com-
paring in vivo and in vitro studies of PRP [78,182-184],
but the present review furnished numeric data for making
comparisons and drawing conclusions. Altogether, these
numbers demonstrated that the high expectations created
by PRP’s outstanding performance when tested in vitro
have not been fulfilled when studies have been performed
in living subjects. Given the small number of experimental
studies with negative results, factors that could have
adversely affected the outcomes were searched. Among
the experimental in vivo studies that yielded negative
results, four included mechanical evaluations in their out-
come measures. Two studies exhibited side effects associ-
ated with PRP administration, and one study failed to
show improvements during the histological evaluation of
experimentally induced tendon lesions treated with PRP.
The trend toward failure when mechanical tests were
applied in PRP-treated tissues was already noted in in vivo
studies with mixed results and was more evident when
the follow-up period lasted longer after the PRP interven-
tion. Mechanical tests should be considered when testing
PRP’s effects in experimental models.
Why in vitro positive results outpaced the positive results
observed in clinical and in vivo PRP studies by such a large
margin remains to be determined. The particular character-
istics of these distinct environments may provide clues
about this discrepancy. The in vivo environment presents
several variables that are absent outside of a living organism
and that could interfere with PRP’s effectiveness. However,
the primary advantage of in vitro research is that it allows
for an enormous level of simplification of the system under
study and of the effects of a compound on a system. As a
drawback, in vitro experiments fail to replicate the precise
cellular conditions of a living organism. They are conducted
in a closed system that tend to allow for higher and longer
exposure of cells or explants to a given molecule than the
exposure found in body tissues, which are half open sys-
tems. In vivo, substances cannot easily reach target cells
and are subject to biokinetics, which can result in under-
estimation of their effects [185].
Another relevant aspect that could harm the extrapo-
lation of in vitro results to the in vivo scenario was thelack of consideration of interspecies differences. Numer-
ous experimental in vivo studies have enrolled different
animal models, and this finding could further affect the
interpretation of the results of the efficacy of PRP in
horses and humans.
Overall, PRP has proved to be a safe therapeutic tool,
with few adverse effects observed in the selected articles.
This finding was similar to reports by other authors
[55,164,177,181,186]. Although the in vitro antibacterial
effect of human PRP against methicillin-resistant
Staphylococcus aureus has been demonstrated [187], as
well as those of equine platelet concentrates and platelet-
poor plasma [188] the potential risk for bacterial contam-
ination during PRP processing must be considered.
Conclusion
PRP has demonstrated the potential to exert beneficial
effects in the healing of tendons, ligaments and cartilage,
but definitive clinical evidence of its efficacy remains
lacking. A great amount of literature has been dedicated
to the topic, and well-constructed clinical trials, with
sufficient power and duration to detect differences
between treatments, as well as standardization of prod-
ucts, procedures and conditions to be treated, are as
important as they are scarce.
Our results confirmed that biased, poorly designed
studies, that are not properly controlled or blinded and
that adopt inadequate outcome measures, favored the
observation of positive results. As a consequence of this
finding, the majority of equine clinical studies, which
lacked randomization; blinding; and adequate power,
outcome measures and control groups, yielded positive
results. Similarly, human clinical trials with analogous
undesirable features tended toward positive outcomes.
Although the human clinical trials were better con-
structed than the equine studies, some aspects of their
design must nevertheless be improved to generate strong
evidence regarding the use of PRP in clinical scenarios.
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